Screening of anti-glioma effects induced by sigma-1 receptor ligands: Potential new use for old anti-psychiatric medicines

European Journal of Cancer

Volumn 45, Issue 16, 2009, Pages 2893-2905

  Mégalizzi, Véronique ^a   Decaestecker, Christine ^a   Debeir, Olivier ^a   Spiegl Kreinecker, Sabine ^b   Berger, Walter ^c   Lefranc, Florence ^a,d   Kast, Richard E ^e   Kiss, Robert ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ERASME HOSPITAL   (Belgium)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Cell migration; Cell proliferation; Chemotherapy; Donepezil; Glioblastoma; Mitotic arrest; Sigma receptors

Indexed keywords

4 (N BENZYLPIPERIDIN 4 YL) 4 IODOBENZAMIDE; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; ANTINEOPLASTIC AGENT; BD 1063; DEXTROMETHORPHAN; DONEPEZIL; ELIPRODIL; FLUVOXAMINE; HALOPERIDOL; MEMANTINE; N ALLYLNORMETAZOCINE; PENTOXYVERINE; PR 084; SIGMA 1 OPIATE RECEPTOR; SM 21; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER SCREENING; DRUG STRUCTURE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MITOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANIMALS; ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; RECEPTORS, SIGMA; TUMOR CELLS, CULTURED;

EID: 70350020952     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.07.011     Document Type: Article

References (43)

1. Lefranc F., Brotchi J., and Kiss R. Possible future issues in the treatment of glioblastomas, with a special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23 (2005) 2411-2422
2. van den Bent M.J., Hegi M.E., and Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer 42 (2006) 582-588
3. Ceruti S., Mazzola A., and Abbracchio M.P. Resistance of human astrocytoma cells to apoptosis induced by mitochondria-damaging agents: possible implications for anticancer therapy. J Pharmacol Exp Ther 314 (2005) 825-837
4. Lefranc F., Facchini V., and Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with special emphasis on glioblastomas. Oncologist 12 (2007) 1395-1403
5. Lefranc F., James S., Camby I., et al. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. J Neurosurg 102 (2005) 706-714
6. Gil-Ad I., Shtaif B., Levkovitz Y., et al. Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumours. J Mol Neurosci 22 (2004) 189-198
7. Megalizzi V., Mathieu V., Mijatovic T., et al. 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 9 (2007) 358-369
8. Van Waarde A., Shiba K., de Jong J.R., et al. Rapid reduction of sigma1-receptor binding and 18F-FDG uptake in rat gliomas after in vivo treatment with doxorubicin. J Nucl Med 48 (2007) 1320-1326
9. Vilner B.J., John C.S., and Bowen W.D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumour cell lines. Cancer Res 55 (1995) 408-413
10. Kast R.E. Glioblastoma: looking at the currently marketed sigma-1 agonists and antagonists. Neoplasia 9 (2007) 689
11. Debeir O., Megalizzi V., Warzee N., Kiss R., and Decaestecker C. Videomicroscopic extraction of specific information on cell proliferation and migration in vitro. Exp Cell Res 314 (2008) 2985-2998
12. Decaestecker C., Debeir O., Van Ham P., and Kiss R. Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev 27 (2007) 149-176
13. Branle F., Lefranc F., Camby I., et al. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95 (2002) 641-655
14. Belot N., Rorive S., Doyen I., et al. Molecular characterization of cell substratum attachments in human glial tumours relates to prognostic features. Glia 36 (2001) 375-390
15. Kouwenhoven M.C., Kros J.M., French P.J., et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42 (2006) 2499-2503
16. Berger W., Spiegl-Kreinecker S., Buchroithner J., et al. Over-expression of the human major vault protein in astrocytic brain tumour cells. Int J Cancer 94 (2001) 377-382
17. Allerstorfer S., Sonvilla G., Fischer H., et al. FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. Oncogene 27 (2008) 4180-4190
18. Brown C., Fezoui M., Selig W.M., Schwartz C.E., and Ellis J.L. Anti-tussive activity of sigma-1 receptor agonists in the guinea-pig. Brit J Pharmacol 141 (2004) 233-240
19. John C.S., Vilner B.J., Gulden M.E., et al. Synthesis and pharmacological characterization of 4-(125I)-N-(N-benzyl piperidin-4-yl)-4-iodobenzamide: a high-affinity sigma receptor ligand for potential imaging of breast cancer. Cancer Res 55 (1995) 3022-3027
20. John C.S., Gulden M.E., Li J., et al. Characterization and targeting of sigma receptor binding sites in human prostate tumour cells. Nucl Med Biol 25 (1998) 205-209
21. Cobos E.J., Pozo E.D., and Baeyens J.M. Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells. J Neurochem 102 (2007) 812-825
22. de Costa B.R., He X.S., Dominguez C., et al. A new approach to the design of σ-2-selective ligands: synthesis and evaluation of N-(2-(3,4-dichlorophenyl)ethyl)-N-methyl-2-(1-pyrrolidinyl)ethylamine-related polyamines at σ-1 and σ-2 receptor subtypes. J Med Chem 37 (1994) 314-321
23. Poignet H., Nowicki J.P., and Scatton B. Lack of neuroprotective effect of some sigma ligands in a model of focal cerebral ischemia in the mouse. Brain Res 596 (1992) 320-324
24. Matsumoto R.R., Bowen W.D., Tom M.A., et al. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 280 (1995) 301-310
25. Hashimoto K., Fujita Y., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine role of sigma-1 receptors. Neuropsychopharmacology 32 (2007) 514-521
26. Maurice T., Meunier J., Feng B., Ieni J., and Monaghan D.T. Interaction with sigma(1) protein, but not N-methyl-d-aspartate receptor, is involved in the pharmacological activity of donepezil. J Pharmacol Exp Ther 317 (2006) 606-614
27. Miller S.C. Dextromethorphan psychosis, dependence and physical withdrawal. Addict Biol 10 (2005) 325-327
28. Peeters M., Romieu P., Maurice T., et al. Involvement of the sigma-1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 19 (2004) 2212-2220
29. Lang A., Soosaar A., Koks S., et al. Pharmacological comparison of antipsychotic drugs and sigma-antagonists in rodents. Pharmacol Toxicol 75 (1994) 222-227
30. DeCoster M.A., Klette K.L., Knight E.S., and Tortella F.C. Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res 671 (1995) 45-53
31. Matsumoto A.A., and Mack A.L. (+)-SM21 attenuates the convulsive and locomotor stimulatory effects of cocaine in mice. Eur J Pharmacol 417 (2001) R1-R2
32. Wilson A.A., Dannals R.F., Ravert H.T., et al. Radiosynthesis of sigma receptor ligands for positron emission tomography: 11C- and 18F-labeled guanidines. J Med Chem 34 (1991) 1867-1870
33. Le Mercier M., Lefranc F., Mijatovic T., et al. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 229 (2008) 172-183
34. Kekuda R., Prasad P.D., Fei Y.J., Leibach F.H., and Ganapathy V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun 229 (1996) 553-558
35. Hanner M., Moebius F.F., Flandorfer A., et al. Purification, molecular cloning and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 93 (1996) 8072-8077
36. Prasad P.D., Li H.W., Fei Y.J., et al. Exon-intron structure, analysis of promoter region, and chromosomal localization of the human type 1 sigma receptor gene. J Neurochem 70 (1998) 443-451
37. Bermack J.E., and Debonnel G. Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands. Brit J Pharmacol 134 (2001) 691-699
38. Aydar E., Palmer C.P., and Djamgoz M.B. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res 64 (2004) 5029-5035
39. Spruce B.A., Campbell L.A., McTavish N., et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumour and self-reliant cells and inhibit tumour growth in vitro and in vivo. Cancer Res 64 (2004) 4875-4886
40. Bekier M.E., Fischbach R., Lee J., and Taylor W.R. Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. Mol Cancer Ther 8 (2009) 1646-1654
41. Stone J.M., Arstad E., Erlandsson K., et al. (123)TPCNE - a novel SPET tracer for the sigma-1 receptor: first human studies and in vivo haloperidol challenge. Synapse 60 (2006) 109-117
42. Wei Z., Qi J., Dai Y., Bowen W.D., and Mousseau D.D. Haloperidol disrupts Akt signalling to reveal a phosphorylation-dependent regulation of pro-apoptotic Bcl-XS function. Cell Signal 21 (2009) 161-168
43. Shaw E.G., Rosdhal R., D'Agostino Jr. R.B., et al. Phase II study of donepezil in irradiated brain tumour patients: effects on cognitive function, mood, and quality of life. J Clin Oncol 24 (2006) 1415-1420